News
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
20 Jun 24
News, Intraday Update, Markets, Movers, Trading Ideas
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
20 Jun 24
News, Intraday Update, Markets, Movers, Trading Ideas
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
20 Jun 24
Analyst Color, News, Upgrades, Markets, Trading Ideas
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
20 Jun 24
News, Price Target, Markets, Analyst Ratings, Trading Ideas
TD Cowen Upgrades Ocular Therapeutix to Buy, Raises Price Target to $11
20 Jun 24
News, Upgrades, Price Target, Analyst Ratings
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
14 Jun 24
News, Intraday Update, Markets, Movers, Trading Ideas
Piper Sandler Maintains Overweight on Ocular Therapeutix, Maintains $15 Price Target
14 Jun 24
News, Price Target, Analyst Ratings
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
14 Jun 24
News, Intraday Update, Markets, Movers, Trading Ideas
Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)
14 Jun 24
Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target
14 Jun 24
News, Price Target, Reiteration, Analyst Ratings
Ocular Therapeutix Highlights AXPAXLI SOL-1 Enrollment And Plans Repeat Dosing Study In Wet AMD; Announces 48-Week Data From HELIOS NPDR Study
13 Jun 24
Biotech, News, General
12 Health Care Stocks Moving In Tuesday's After-Market Session
28 May 24
Movers
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Lowers Price Target to $14
8 May 24
News, Price Target, Analyst Ratings
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $22
8 May 24
News, Price Target, Analyst Ratings
TD Cowen Maintains Hold on Ocular Therapeutix, Lowers Price Target to $7
8 May 24
News, Price Target, Analyst Ratings
Ocular Therapeutix Q1 2024 Adj EPS $(0.28) Misses $(0.19) Estimate, Sales $14.774M Miss $15.414M Estimate
7 May 24
Earnings, Earnings Misses, News
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 May 24
Movers
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
6 May 24
News, Pre-Market Outlook, Markets, Movers, Trading Ideas
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $16 Price Target
19 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
18 Apr 24
Biotech, News, Health Care, Top Stories, Movers, Trading Ideas, General
Press releases
Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study
13 Jun 24
Press Releases
Ocular Therapeutix® to Host Investor Day on June 13, 2024
5 Jun 24
News, Press Releases
Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Jun 24
Markets, Press Releases
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
9 May 24
News, Press Releases
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 May 24
News, Financing, Press Releases
Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
6 May 24
News, Health Care, Press Releases
Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
3 May 24
News, Press Releases
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024
1 May 24
News, Press Releases
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
18 Apr 24
Health Care, Press Releases
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
16 Apr 24
News, Management, Press Releases
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
15 Apr 24
News, Management, Press Releases
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
9 Apr 24
Press Releases
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
6 Apr 24
News, Analyst Ratings, Press Releases
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
26 Mar 24
News, Press Releases